One of Australia’s largest cannabis and hemp firms is struggling on the open market as it looks to sell off some of its assets in an effort to focus on the hemp-derived cannabidiol (CBD) market.

Shares of Elixinol Global (ASX:EXL,OTC Pink:ELLXF) slumped 25 percent from market close on Friday (January 31) to the start of the trading session on Monday (February 3) after it told investors it is selling its subsidiary Hemp Foods Australia to a Chinese manufacturing company for AU$500,000.


The cannabis producer is also halting its plans to apply for a medical cannabis cultivation licence for its Nunyara subsidiary and is selling all the assets attached to this operation, including a plot of land.

 

BRAND NEW! Take Advantage Of Silver On The Rise Before It's Too Late

   
PROMISING Stock Picks! EXCLUSIVE Interviews! JUST RELEASED Trends!
   
Everything You Need To Watch The Dollars Come Pouring In!
 

Elixinol ended the trading day on Thursday (February 6) at a price of AU$0.69 per share.

With the two sales, Elixinol is looking at a total of AU$17.3 million in impairment fees.

Hemp Foods Australia will be sold to a subsidiary of Shanghai Shunho New Materials Technology Co. (SZSE:002565), though the completion of the sale is still dependent on a purchase agreement between the two companies. This deal will name Shunho as the exclusive manufacturer and distributor of Elixinol’s CBD products in China, Hong Kong, Taiwan and Macau.

As a part of the three year licencing agreement, Elixinol will have the ability to audit and inspect the materials, facilities and Elixinol-branded products under Shunho’s name to ensure standards are met.

The sale is set to be completed sometime in the first quarter of 2020, Elixinol said in a press release, and carries a fee of AU$12.5 million. However, the company said the transaction will improve future cash flow and will allow it to focus on its CBD businesses.

“During negotiations of the sale of (Hemp Foods Australia), it became apparent that Elixinol could benefit from Shunho’s extensive experience and reputation in Greater China,” Stratos Karousos, Elixinol Group’s CEO, said in a statement.

The executive said the firm plans to leverage Shunho’s experience in hemp cultivation and distribution across Asia to help follow through with its global strategy.

The Nunyara business was founded in 2014 with the goal of entering the Australian medical cannabis market, and slashing it from its roster will cost Elixinol AU$4.8 million in a non-cash impairment fee.

Nunyara was granted a licence for the production of medicinal cannabis for extracts and tinctures of cannabis and cannabis resin back in July 2019. At the time, the firm expected to obtain a full medicinal cannabis Llicence from the Australian Office of Drug Control.

The sale of the two subsidiaries comes after Elixinol discarded its majority stake in Elixinol Japan by selling it to Takeshi Sakurada, a fellow shareholder, in December.

The firm’s Japanese division was found to have sold non-compliant hemp-derived CBD products during a company-wide review of its global operations.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

 

Introducing Our NEW Gold Outlook Report

   
BURSTING With Exclusive Information Not Found Anywhere Else. Don't Get Left Behind!
Grab Your FREE Gold Report Today!
 
  • Company has received UK Continuing Professional Development (“CPD”) accreditation for its global education platform, Khiron Academy
  • UK medical professionals may now earn CPD credits through Khiron’s medical cannabis education program
  • The Company has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK, to increase patient access via medical cannabis education
  • As a leading international medical cannabis educator, nearly 1,000 medical professionals in Latin America and the United Kingdom have registered for, or completed, Khiron Academy training

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe is pleased to announce it has received UK Continuing Professional Development (“CPD”) accreditation for Khiron Academy, the Company’s global medical cannabis education platform.

Additionally, following its accreditation, the Company has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK and fellow founding member of Project Twenty21, to increase patient access through medical cannabis education initially. Khiron Academy will be made available to prescribers in the UK that have registered with Cellen’s MedCanHub, an emerging education portal. Cellen is market leader, widely recognized for also launching the UK’s first digital pain clinic, Leva.

Keep reading... Show less

TRACE’s plant-based and alkaline wellness products to expand into key markets of Japan, China and the Philippines

Emerging leader in innovative health and wellness beverages and consumer products, BevCanna Enterprises Inc . ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today its anticipated expansion into the Asia Pacific region, through its wholly-owned subsidiary Naturo Group. After completing a comprehensive market, distribution and partner assessment, the Company intends to initially launch its portfolio of TRACE health and wellness products in the key markets of Japan, China, and the Philippines, through multi-channel distribution outlets including e-commerce, retail, and wholesale.

Keep reading... Show less

Trulieve acquires dispensary permits from Solevo Wellness West Virginia LLC for $650,000

Trulieve Cannabis Corp . (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States and the largest cannabis company in Florida announced today that it acquired Solevo Wellness West Virginia LLC (“Solevo”) and its three West Virginia dispensary permits for $650,000 . Solevo was awarded two permits in Morgantown and one in Parkersburg in January 2021 as part of the West Virginia application process.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) a wellness company that develops and sells sustainable, plant-based products, is pleased to announce that it’s Jusu Home and Body line is now available for purchase on Faire Wholesale Marketplace (“Faire” or “www.faire.com”), an online wholesale marketplace valued at US $2.5 billion. Jusu Home and Body products are currently featured in their “New Arrivals” section.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/80230_8c77c54544bf884c_001.jpg

Keep reading... Show less

 Aion Therapeutic Inc. (CSE: AION) (” Aion Therapeutic ” or the ” Company “) today announced that it has retained KCSA Strategic Communications (” KCSA “), a leading New York City -based communications firm.

Keep reading... Show less